Next report date
Report period
Q2 2024
EPS estimate
0.02EUR
Revenue estimate
44.60 MEUR
0.10EUR
1.14 MEUR
158.15 MEUR
14.34 M
About PHARMA MAR, S.A.
Sector
CEO
José Maria Fernández de Sousa-Faro
Headquarters
Colmenar Viejo
Website
Founded
1986
ISIN
ES0169501022
FIGI
BBG00Y63DGS2
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.
Pharmamar PHMGood morning, today I present the analysis of PHM, a Spanish company pharmamar in the race for the vaccine against Covid19.
It is being a great trading year for this company.
The bullish structure marked by the yellow arrow has been broken, but the new structure, the bearish one, has not yet consoli
Pharmamar may reach 7,06€ +50%It seems that Pharmamar may reach 7,06€ (+50% from current price) after activating an iSHS and improving its rating.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0RC6 is 30.76 EUR — it has increased by 0.39% in the past 24 hours. Watch PHARMA MAR SA EUR0.6 POST CONSOLIDATION stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSIN exchange PHARMA MAR SA EUR0.6 POST CONSOLIDATION stocks are traded under the ticker 0RC6.
PHARMA MAR SA EUR0.6 POST CONSOLIDATION is going to release the next earnings report on Jul 25, 2024. Keep track of upcoming events with our Earnings Calendar.
0RC6 stock is 2.25% volatile and has beta coefficient of 0.84. Track PHARMA MAR SA EUR0.6 POST CONSOLIDATION stock price on the chart and check out the list of the most volatile stocks — is PHARMA MAR SA EUR0.6 POST CONSOLIDATION there?
0RC6 earnings for the last quarter are −0.38 EUR per share, whereas the estimation was 0.08 EUR resulting in a −575.00% surprise. The estimated earnings for the next quarter are −0.07 EUR per share. See more details about PHARMA MAR SA EUR0.6 POST CONSOLIDATION earnings.
PHARMA MAR SA EUR0.6 POST CONSOLIDATION revenue for the last quarter amounts to 40.75 M EUR despite the estimated figure of 41.80 M EUR. In the next quarter revenue is expected to reach 36.08 M EUR.
Yes, you can track PHARMA MAR SA EUR0.6 POST CONSOLIDATION financials in yearly and quarterly reports right on TradingView.
0RC6 stock has risen by 6.81% compared to the previous week, the month change is a 7.93% rise, over the last year PHARMA MAR SA EUR0.6 POST CONSOLIDATION has showed a 17.22% decrease.
0RC6 net income for the last quarter is 2.30 M EUR, while the quarter before that showed −6.82 M EUR of net income which accounts for 133.73% change. Track more PHARMA MAR SA EUR0.6 POST CONSOLIDATION financial stats to get the full picture.
Today PHARMA MAR SA EUR0.6 POST CONSOLIDATION has the market capitalization of 543.02 M, it has decreased by 0.08% over the last week.
Like other stocks, 0RC6 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMA MAR SA EUR0.6 POST CONSOLIDATION stock right from TradingView charts — choose your broker and connect to your account.
0RC6 reached its all-time high on Jul 16, 2020 with the price of 137.64 EUR, and its all-time low was 10.74 EUR and was reached on Oct 26, 2018. View more price dynamics on 0RC6 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHARMA MAR SA EUR0.6 POST CONSOLIDATION technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHARMA MAR SA EUR0.6 POST CONSOLIDATION stock shows the sell signal. See more of PHARMA MAR SA EUR0.6 POST CONSOLIDATION technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on PHARMA MAR SA EUR0.6 POST CONSOLIDATION future price: according to them, 0RC6 price has a max estimate of 70.00 EUR and a min estimate of 29.60 EUR. Watch 0RC6 chart and read a more detailed PHARMA MAR SA EUR0.6 POST CONSOLIDATION stock forecast: see what analysts think of PHARMA MAR SA EUR0.6 POST CONSOLIDATION and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMA MAR SA EUR0.6 POST CONSOLIDATION EBITDA is −1.84 M EUR, and current EBITDA margin is 0.26%. See more stats in PHARMA MAR SA EUR0.6 POST CONSOLIDATION financial statements.